BIOGEN INC. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2010 to Q1 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Biogen Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q1 2024.
- Biogen Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $39.9M.
- Biogen Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$306M, a 81.4% decline from 2022.
- Biogen Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$169M, a 60.5% increase from 2021.
- Biogen Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$427M, a 386% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)